Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

First 24 hours shape the body's antiviral defense response

19

Aug 2026

First 24 hours shape the body's antiviral defense response

Age, genetics and lifestyle are known to influence how people respond to viral infections. Scientists also know that differences in immune response play an important role, but exactly how these factors shape the course of an infection has remained unclear.

New studies reveal hidden control hub for MYC-driven cancers

19

Aug 2026

New studies reveal hidden control hub for MYC-driven cancers

In a rare pair of papers published back-to-back in the journal Genes & Development, research teams led by senior author Anindya Bagchi, PhD, associate professor in the Cancer Genome and Epigenetics Program at Sanford Burnham Prebys Medical Discovery Institute, establish a unified framework that governs one of cancer's most powerful master regulators.

A single blood test could offer a glimpse of disease risk years in advance

19

Aug 2026

A single blood test could offer a glimpse of disease risk years in advance

Machine learning-derived cellular aging clocks mapped more than 7,000 plasma proteins to over 40 cell types, revealing marked differences in how individual cell populations age. These blood-based signatures were associated with future risks of Alzheimer’s disease, ALS, lung cancer, type 2 diabetes, and mortality across follow-up extending to 15 years.

Review reveals how nicotine damages blood vessels and heart health

19

Aug 2026

Review reveals how nicotine damages blood vessels and heart health

A review published today in Nature Reviews Cardiology provides the most detailed picture yet of how nicotine damages the cardiovascular system – tracing the biological chain of events from the moment nicotine binds to receptors in blood vessel walls through to the atherosclerotic plaque rupture that triggers heart attacks and strokes.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.